e-therapeutics plc (LON:ETX – Get Free Report)’s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 9.76 ($0.13) and traded as high as GBX 10.75 ($0.14). e-therapeutics shares last traded at GBX 9 ($0.12), with a volume of 2,518,125 shares changing hands.
e-therapeutics Trading Down 6.7 %
The company has a debt-to-equity ratio of 0.33, a current ratio of 22.20 and a quick ratio of 20.13. The firm has a fifty day simple moving average of GBX 9 and a two-hundred day simple moving average of GBX 9.73. The firm has a market capitalization of £52.59 million, a P/E ratio of -450.00 and a beta of 0.46.
About e-therapeutics
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet.
See Also
- Five stocks we like better than e-therapeutics
- Investing In Preferred Stock vs. Common Stock
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- 3 Warren Buffett Stocks to Buy Now
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Manufacturing Stocks Investing
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for e-therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for e-therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.